Table 2 Available epinephrine autoinjectors in Canada with current product monograph at time of publication and CSACI recommendations
From: CSACI position statement: transition recommendations on existing epinephrine autoinjectors
Brand | Available doses (mg) | Product monograph recommendations | CSACI recommendations |
|---|---|---|---|
EpiPen® | 0.30 | For those who weigh ≥ 30 kg | EpiPen® is recommended for those ≥ 25 kg |
EpiPen Jr® | 0.15 | For those who weigh between 15 and 30 kg | For those < 25 kg, the EpiPen Jr® is recommended |
Allerject® | 0.30 | For those who weigh ≥ 30 kg | For those ≥ 25 kg, the Allerject® 0.30 mg is recommended |
Allerject® | 0.15 | For those who weigh 15–30 kg | For those < 25 kg, the Allerject® 0.15 mg is recommended |
Emerade™ | 0.50 | Adult: > 60 kg: 0.3 to 0.5 mg depending on clinical judgement | For those ≥ 45 kg, the Emerade™ 0.5 mg is recommended |
Emerade™ | 0.30 | Pediatric: Children > 30 kg: 0.3 mg | For those ≥ 25 kg to < 45 kg, the Emerade™ 0.30 mg is recommended |
Adolescent > 30 kg: The dosage recommendations for adult patients should be followed | |||
Adult: < 60 kg: 0.3 mg |